Kornimate/medical-research-clean huggingface dataset:
mesenchymal stem cells transplantation for refractory systemic lupus erythematosus (sle)

Conditions: Refractory Systemic Lupus Erythematosus

Summary: this study will explore a new approach to treat patients with a medical condition known as systemic lupus erythematosus (sle) who have been resistant to previous treatments using a new population of cells with capability to restore a normal immune system that will no longer attack the body. the stated hypothesis is that the sle condition is caused by an abnormal immune system that can be restored by replenishing the body with a new population of progenitor cells.

the purpose of this study is to evaluate the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell (allomsc) transplantation in patients with refractory sle. patients with lupus nephritis and refractory to corticosteroid or cyclophosphamide trials will be enrolled in this trial. the treatment intervention includes a 24 hour pretreatment with cyclophosphamide followed by allomsc transplantation. patients will be admitted to the in-patient service for the 3-5 days for the transplant treatment and will be followed up in the outpatient clinic. all baseline lupus serology, renal function panels will be obtained at pre-treatment admission. post-transplantation follow-up visits will be at monthly intervals for lupus serology and renal function tests, and every 3 months for analysis of t regulatory population. the transplanted patients will be evaluated by an integrated team of rheumatologists, hematologists and bone marrow transplant specialists every month for the entire duration of the trial (2 years) and every 6-12 months thereafter.

Eligibility criteria:
inclusion criteria: * all patients fulfilled the american college of rheumatology (acr) criteria of sle, man or woman aged from 15 to 70 years old, sledai≥8; * lupus nephritis with 24h urine protein≥1g; * refractory disease as determined by failure of the following regimens: * trial of corticosteroids (oral prednisone more than 20 mg/day); * trial of cyclophosphamide 0.4 \~ 0.6 / m2 every two weeks for six months, or other immunosuppressive drugs, such as mmf 2 g / day, for three months; * patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital; * willing to use contraception throughout the study and for 12 mos following treatment. exclusion criteria: * abnormal liver function (alt higher than 3 times the normal value); * end-stage renal failure; * severe heart and pulmonary failure, or other important organs damage; * undercontrolled infections * pregnant or breast feeding women, male or female who intended to recent pregnancy.

Keywords: lupus erythematosus,systemic lupus nephritis mesenchymal stem cells transplantation
comparison of efficacy of vitamin d and vitamin d-calcium fortified yogurt drink in diabetic patients

Conditions: Type 2 Diabetes

Summary: the aim of this study is to evaluate the possible effects of daily intake of yogurt drink fortified with vitamin d alone or with vitamin d + calcium on some selected glycemic, metabolic, inflammatory and oxidative stress markers in patients with type 2 diabetes (t2dm).

ninety diabetic patients will be selected. patients who are receiving vitamin d, calcium or omega-3 supplements within the last three months will be excluded. patients will be assigned randomly to one of the three intervention groups. 1. plain yogurt drink 2. vitamin d-fortified yogurt drink 3. vitamin d-calcium fortified yogurt drink. each patient will consume 2 servings of yogurt drink every day for 3 months with lunch and dinner. at the first and last visits, dietary and laboratory assessments will be performed for all patients. primary outcomes are improvement in glycemic, inflammatory and immunity markers and secondary outcome is prevention of long-term diabetic complications.

Eligibility criteria:
inclusion criteria:age: * 30 to 50 years, * fasting blood glucose ≥ 126 mg/dl exclusion criteria: * receiving vitamin d or calcium or omega-3 supplements within the last three months, * on any medication which could potentially influence vitamin d metabolism (notably estrogens, and calcitonin) within the last three months, * any other concomitant disease such as renal, hepatic, and other endocrinological disorders, and malignancies, which could influence vitamin d metabolism. * receiving insulin or any change in the type and/or dose of the current hypoglycemic medications

Keywords: vitamin d fortification yogurt drink type 2 diabetes efficacy
characteristics of abdominal fluid in patients with diverticulitis hinchey iii or iv

Conditions: Perforated Diverticulitis

Summary: perforated diverticulitis of the colon can be complicated by peritonitis, either purulent or fecal. both are life threatening conditions requiring emergency surgery. the background in terms of reasons for inflammation (diverticulitis) and perforation to develop is unknown. in this study we focus on specific changes associated with inflammation, both in tissues and of fecal and mucosal microbiota.

a prospective study of abdominal fluid, periferal blood, tissues as well as feces in patients (perforated diverticulitis with peritonitis undergoing emergency surgery, group i), and in controls (patients operated due to colorectal cancer, group ii; patients with mild diverticulitis not needing surgery, group iii). immune acitvity in abdominal fluid and periferal blood by immunoassay of 92 individual proteins. mrna expression of 96 specific genes in tissue samples. quatification of bacterial diversity in feces and colon mucosa.

Eligibility criteria:
inclusion criteria: * signs of perforated diverticulitis with peritonitis and decision to perform emergency surgery (group i) * signs of acute diverticulitis and no decision of emergency surgery (group ii) * patients with colorectal cancer planned for elective surgery (group iii) exclusion criteria: * no surgery performed (group i and iii) * withdrawn consent (any group)

Keywords: perforated diverticulitis peritonitis protein changes microbiota
comparison of lower limb endovascular interventions with and without the endonaut workstation

Conditions: Peripheral Arterial Disease

Summary: to demonstrate that the use of endonaut for endovascular procedures on the femoropopliteal axis has a clinical impact for the patient (decrease in irradiation and the volume of contrast product) as well as for nursing staff (reduction in irradiation) compared to procedures performed without endonaut.

peripheral artery disease (pad) is characterized by a narrowing of the size of arteries, which resulting in a loss of hemodynamic load. endovascular (or percutaneous) procedures performed at the infrainguinal level (axefemoro-popliteal) are very common in affected patients. therenva offers a complete and consistent lightweight navigation solution (endonaut®) based on artificial intelligence (ai) algorithms, and providing technology accessible to all operating rooms for pad procedures. the aim of this study is to demonstrate that the use of endonaut for endovascular procedures on the femoropopliteal axis has a clinical impact for the patient (decrease in irradiation and the volume of contrast product) as well as for nursing staff (reduction in irradiation) compared to the procedures performed by endonaut.

Eligibility criteria:
inclusion criteria: * patients with peripheral arterial disease of the lower limbs, all clinical stages, lesions of the femoro-popliteal stage and candidates for endovascular treatment of these lesions. * major patients * patients not opposed to their participation in the study exclusion criteria: - patients requiring conventional surgical revascularization.
effect of ultrasonic activation of bioceramic sealer on postoperative pain in lower premolars

Conditions: Symptomatic Irreversible Pulpitis

Summary: the aim of this study is to clinically compare post-operative pain levels after ultrasonic activation of ceraseal bioceramic sealer versus non-activated bioceramic sealer for patients with symptomatic irreversible pulpitis related to mandibular premolar teeth.

to clinically compare post-operative pain levels after ultrasonic activation of ceraseal bioceramic sealer versus non-activated bioceramic sealer for patients with symptomatic irreversible pulpitis related to mandibular premolar teeth.ultrasonic activation of ceraseal bioceramic sealer for 20 seconds using non cutting ultrasonic tip.

Eligibility criteria:
inclusion criteria: * patients above 18 years old and to 50. * male or female. * patients seeking root canal treatment. * mandibular posterior teeth with symptomatic irreversible pulpitis with preoperative sharp, moderate, or severe pain with normal periapical radiographic appearance or slight widening in lamina dura. * systematically healthy patient (asa i, ii). * patient who can understand modified vas and sign informed consent exclusion criteria: * medically compromised patients having significant systemic disorders. (asa iii or iv). * history of intolerance to nsaids. * patients with two or more adjacent teeth requiring endodontic treatment. * external root resorption. * internal root resorption. * vertical root fracture. * periapical lesion. * association with swelling. * acute peri-apical abscess or acute exacerbation of a chronic abscess. * pregnancy. * use of ibuprofen in the last 12 hour. * bleeding disorder. * long term corticosteroid use. * mobility grade ii or iii. * pocket depth more than 5mm. * previous root canal therapy. * non-restorability. * tmj problems, bruxism, clenching or traumatic occlusion. * inability to perceive the given instructions
remineralization effect of eggshell powder on post-orthodontic white spot lesions compared to cpp-acp

Conditions: Dental Caries

Summary: this research is conducted to compare the remineralization efficacy of eggshell powder gel and cpp-acp (mi paste) on post-orthodontic white spot lesions.


Eligibility criteria:
inclusion criteria: * a patient who has just completed a comprehensive orthodontic treatment. * presence of at least one wsl, diagnodent score (0-20). * age range between 13 and 35years. exclusion criteria: * patients are unable to return for recall appointments. * high caries risk. * have plaque accumulation and a periodontal problem * in progress treatment of chronic disease. * presence of abnormal oral, medical, or mental condition (including any milk-related allergies or any medical condition involving kidneys or salivary glands). * presence of dentin caries, enamel hypoplasia or restorations on maxillary anterior teeth.
inhaled iloprost as an adjunct to inhaled nitric oxide in pediatric critical care patients

Conditions: Pulmonary Hypertension; Neonatal Hypoxic Respiratory Failure; Persistent Pulmonary Hypertension of Newborn; Congenital Heart Defects; Acute Respiratory Distress Syndrome

Summary: the purpose of this study is to determine whether inhaled iloprost is safe and effective in pediatric patients with pulmonary hypertension who are sick in the intensive care unit.

inhaled nitric oxide (no) is used in the management of all causes of pediatric pulmonary hypertension. despite widespread use of nitric oxide to treat critically ill mechanically-ventilated pediatric patients with pulmonary hypertension, response to therapy is not universal. nitric oxide fails to improve oxygenation in approximately 30% of these patients. nonresponders to nitric oxide have few treatment options. iloprost is the only other medication approved for inhalational delivery in the treatment of pulmonary hypertension. inhalation therapy for pulmonary vasodilatation in critically ill children is inherently more attractive than oral or intravenous therapies due to the ability to deliver medication directly to the lung and to decrease systemic effects. the use of inhaled iloprost has been reported to decrease pulmonary vascular resistance in many pediatric pathologic settings, including combination therapy with nitric oxide.

Eligibility criteria:
inclusion criteria: * birth to 21 years of age * diagnosis of pulmonary hypertension must fit into one of three categories * neonatal hypoxic respiratory failure * congenital heart disease * acquired/acute respiratory distress syndrome (lung disease) * parents of subject must be able and willing to give written informed consent and comply with the requirements of the study protocol and must authorize release and use of protected health information * patients who remain on nitric oxide at 12 to 18 hours after initiation * patients who are transferred to an intensive care unit already on inhaled nitric oxide from another institution will be treated as if nitric oxide therapy was started at the time of admission to the unit * patients will be enrolled only after a clinical decision to treat with nitric oxide has been made by the treating physician exclusion criteria: * corrected gestational age less than 35 weeks * patients with potentially fatal non-cardiopulmonary co-morbidities (e.g. hepatic, neurologic, renal) * known or suspected fatal genetic syndrome * patient with cardiac failure secondary to significant left-sided obstructive lesions * patient on ecmo * patient on any other form of prostacyclin * patient on any medication with known no production, e.g., nitroprusside * patient on an endothelin receptor antagonist (e.g. bosentan) * patient on sildenafil * patient on whom clinicians do not agree to follow standard inhaled nitric oxide weaning protocol * patients who have known hypersensitivity to prostacyclin or any of its components * patient who is pregnant * patient with platelet count less than 50,000

Keywords: iloprost nitric oxide mechanical ventilator
hrv in patients treated with spinal cord stimulation

Conditions: Failed Back Surgery Syndrome

Summary: this study is an observatory single center study investigating heart rate variability during on and off states of the spinal cord stimulator, in patients with failed back surgery syndrome.


Eligibility criteria:
inclusion criteria: * subject is at least 18 years old. * diagnosis of fbss (failed conservative treatments for pain including but not limited to pharmacological therapy and physical therapy) and currently being treated with spinal cord stimulation. * cognitive and language functioning enabling coherent communication between the examiner and the participant. exclusion criteria: * the presence of one or more coexisting conditions known to affect hrv analysis (including but not limited to atrial fibrillation, numerous atrial or ventricular extra beats, paced rhythm, left ventricular bundle branch block, cancer, kidney or hepatic failure, and diabetes mellitus (autonomic nervous system dysfunction)). * the use of medication that directly modifies autonomic control (for example beta-blockers).

Keywords: spinal cord stimulation heart rate variability
value of heart rate lowering therapy in acute myocarditis

Conditions: Myocarditis

Summary: to study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without lv dysfunction.


Eligibility criteria:
inclusion criteria: * adults: ≥18 years of age. * presentation: at least one of the following: * myopericarditis/acs-like * minoca * arrhythmias: brady or tachyarrhythmias. * unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically). * tte: lvef\>40% * cmr-confirmed myo(peri)carditis (lake louise criteria) exclusion criteria: * • rheumatic carditis. * connective tissue diseases (-ve ana). * cancer chemotherapy. * toxicity from immunotherapy. * vaccine-related myocarditis. * presence of coronary artery disease. * peripartum (occurring during the last month of pregnancy or within 5 months after delivery) * ecg: atrial fibrillation/flutter. * resuscitated sudden death. * early/initial phase of decompensated heart failure. * tamponade complicating pericarditis unless successfully managed.
safety and efficacy of mk-1200 in participants with advanced solid tumors (mk-1200-002)

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to assess the efficacy and safety of mk-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (gej) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. part 1 of the study will be a dose escalation to determine the maximum tolerated dose (mtd). part 2 will evaluate safety and efficacy of mk-1200 at 2 different doses


Eligibility criteria:
inclusion criteria: * confirmed advanced (unresectable and/or metastatic) solid tumor: gastric cancer (including gastroesophageal junction cancer), esophageal cancer, biliary tract cancer, or pancreatic ductal adenocarcinoma * participants who experienced adverse events (aes) due to previous anticancer therapies must have recovered to \< grade 1 or baseline * human immunodeficiency virus (hiv)-infected participants must have well controlled hiv on antiretroviral therapy * hepatitis b surface antigen (hbsag) positive participants are eligible if they have received hepatitis b virus (hbv) antiviral therapy for at least 4 weeks and have undetectable hbv viral load * participants with a history of hepatitis c virus (hcv) infection are eligible if hcv viral load is undetectable * received and progressed on or after 1 or 2 prior lines of therapy exclusion criteria: * active severe digestive disease * history of acute myocardial infarction; unstable angina; stroke or transient ischemic attack within 6 months prior to the first dose of study intervention * diabetes or hypertension that cannot be controlled by medication * hiv-infected participants with a history of kaposi's sarcoma and/or multicentric castleman's disease * received prior systemic anticancer therapy including investigational agents within 4 weeks before study intervention * received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * known additional malignancy that is progressing or has required active treatment within the past 2 years * known active central nervous system (cns) metastases and/or carcinomatous meningitis * active infection requiring systemic therapy * have not adequately recovered from major surgery or have ongoing surgical complications
epilepsy and driving.

Conditions: Epilepsy

Summary: epilepsy can lead to cognitive impairments, particularly in attention, which may affect daily activities such as driving. driving plays a key role in maintaining autonomy and is essential for the social and professional integration of people with epilepsy. therefore, assessing fitness to drive is a major issue for individuals with epilepsy. french legislation governing driving for people with epilepsy clearly outlines the periods during which a person is not permitted to drive. however, the means or methods for evaluating driving fitness in these individuals are not well defined. currently, assessment is based more on a medical consultation than on a comprehensive evaluation of driving ability. using a driving simulator in combination with an eeg could be a valuable approach to better assess the impact of epilepsy-related cognitive impairments on driving performance.


Eligibility criteria:
inclusion criteria * aged between 18 and 65 years * holder of a category b driving license * active driver: drives at least once a month * no medical condition contraindicating driving, except for epilepsy * provides explicit consent to participate in the study * affiliated with or a beneficiary of a social security scheme exclusion criteria: * subject to legal protection (guardianship and curatorship are accepted for individuals with epilepsy, as this population represents a significant proportion of our institution's patients) * pregnant or breastfeeding women * known cybersickness (virtual reality or simulator sickness)
a study to learn about lorlatinib in patients with non-small cell lung cancer which could not be controlled

Conditions: Non-Small Cell Lung Carcinoma

Summary: the purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled. this study is seeking participants who: * have lung cancer that could not be controlled. * have a type of gene called anaplastic lymphoma kinase. a gene is a part of your dna that has instructions for making things your body needs to work. * have received at least 1 treatment before. all participants in this study had received lorlatinib. lorlatinib is a tablet that is taken by mouth at home. they continued to take dacomitinib until their cancer was no longer responding. the study will look at the experiences of people receiving the study medicine. this will help to see if the study medicine is safe and effective.

non-small cell lung cancer (nsclc; 80-85% of all lung cancers) remains the most common cause of cancer-related mortality globally, most often diagnosed in advanced stages. targeted drugs are currently the most often used therapies for advanced nsclc patients that harbor molecular alterations, including the echinoderm microtubule-associated protein like 4 (eml4)-anaplastic lymphoma kinase (alk) translocation. for alk-positive nsclc patients, crizotinib, ceritinib, alectinib, and brigatinib, are the first- and second-generation tyrosine kinase inhibitors (tkis). although the benefit of them has been demonstrated in series of pivotal clinical trials, most patients who initially derive the benefit latterly develop resistance due to secondary mutations. lorlatinib, a third-generation inhibitor, is a tki of alk and receptor tyrosine kinase c-ros oncogene i (ros-1). it is also a potent tki that is effectively against known resistant mutants that mediate resistance to first- and second-generation alk-tkis. despite the efficacy and safety data derived from the pivotal phase i/ii clinical trial, there are limited data describing the use of lorlatinib and its outcomes in real-world practice settings outside the highly controlled environs of clinical trials. the objective of this study is therefore to evaluate real-world systemic treatment patterns, clinical outcome, therapeutic effect, safety profile of lorlatinib in advanced nsclc patients, and also factors associated with clinical outcome in those lorlatinib treated patients.

Eligibility criteria:
inclusion criteria: * age ≥ 20 years old * patients who were approved to join lorlatinib cup on or before 31 jul 2019 while initiate lorlatinib treatment before 30 sep 2019, * evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. exclusion criteria: * patient treated lorlatinib other than cup.

Keywords: alk tki lorlatinib rwe
predicting the long-term response of high frequency spinal cord stimulation in patients with failed back surgery syndrome.

Conditions: Failed Back Surgery Syndrome

Summary: the aim of the current retrospective study is to predict responders for hf10-scs therapy by only using baseline data. data collected through clinical practice until june 2020 will be used in this retrospective analysis.


Eligibility criteria:
inclusion criteria: * fbss patients treated with high frequency spinal cord stimulation implantation.

Keywords: high frequency spinal cord stimulation prediction